| Date | Title | Description |
| 15.05.2024 | Most-Active US Investors: Sequoia, Khosla, General Catalyst Lead Strong Pack In April | 9 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 30.04.2024 | Rippl acquires Kinto | Rippl, a Seattle, WA-based dementia-focused specialty care provider, announced it has acquired Kinto, a Boston, MA-based provider of an AI-enabled dementia caregiver support platform.
The amount of the deal was not disclosed.
This combinati... |
| 25.04.2024 | Xaira Therapeutics: A Billion-Dollar Bet on AI Drug Discovery | In the fast-paced world of tech and biotech, Xaira Therapeutics emerges as a powerhouse with a massive $1 billion in funding. Led by CEO Marc Tessier-Lavigne, a former Stanford president and Genentech chief scientific officer, Xaira is read... |
| 24.04.2024 | Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs | Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery.
On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of... |
| 12.04.2024 | Most-Active US Investors: General Catalyst Tops March’s List | 3 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 02.04.2024 | Autism Impact Fund closes $60M first fund and broadens its scope | Millions of people around the world are affected by autism spectrum disorder (ASD). Both as kids and later in life, these individuals and their families need better detection, treatment and support solutions that will help them live with au... |
| 02.02.2024 | ARCH Venture Partners is raising $3 billion for a life sciences fund | ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake... |
| 25.07.2023 | Molecular farming: IngredientWerks grows heme protein in corn at ‘unprecedented low cost’ | Molecular farming startup IngredientWerks has genetically engineered corn crops to express high levels of bovine myoglobin in a process it claims can scale at a fraction of the cost of precision fermentation.
A heme-binding protein found in... |
| 11.04.2023 | Recuro Health Closes $47 Million Series B Financing Led by ARCH Venture Partners, Advancing Innovative Virtual-First Care Service | DALLAS–(BUSINESS WIRE)–April 11, 2023–
Recuro Health (Recuro), an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused model to a proactive care approach, today annou... |
| 07.03.2023 | ARCH leads Volastra $60 million financing round | - |
| 27.01.2023 | Paradigm Launches with $203M to Improve Clinical Research Access | What You Should Know:
Paradigm’s financing was co-led by ARCH Venture Partners and General Catalyst and joined by funds including F-Prime Capital, GV, LUX Capital, Mubadala Capital, and Magnetic Ventures, and strategic investors including t... |
| 28.09.2022 | Rippl Launches with $35M to Transform Mental Health for Seniors | What You Should Know:
Mental and behavioral health for seniors is a massive hidden public health crisis. The total national cost of care for dementia patients, including those with Alzheimer’s disease, is projected to be $321 billion in 202... |
| 20.09.2022 | Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies | What You Should Know:
Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondri... |
| 29.08.2022 | Sneaky synthetic molecules open the way for new types of drugs and a new startup | An illustration shows how custom-made peptide molecules (shown in pink and purple) can slip through a cell membrane. (Image by Ian C. Haydon / UW Institute for Protein Design)
Researchers at the University of Washington have discovered how ... |
| 29.06.2022 | ARCH Venture Partners Announces $2.975 Billion Fund XII to Create and Fund Early Stage Biotechnology Companies | - |
| 29.06.2022 | Arch Venture Partners Closes Fund XII, at $2.975 Billion | Arch Venture Partners, a Chicago, IL-based venture capital firm, closed Arch Venture Fund XII, at $2.975 billion.
The fund will invest in the creation, development and funding of early stage biotechnology companies with potential to solve s... |
| 29.06.2022 | ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn | - |
| 29.06.2022 | 'Science doesn't care' about markets: Arch raises nearly $3B amid tough times for biotechs | Arch Venture Partners is out to prove there’s still money for the taking for up-and-coming biotechs, raising nearly $3 billion for its latest fund amid a tumultuous bear market.
The company was relatively vague on what the money for its twe... |
| 19.05.2022 | Can We Fix Ovarian Aging? Here Is One Startup Up For The Task! | Concept of a healthy female reproductive system. getty |
| 14.04.2022 | ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer | - |
| 20.01.2022 | ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital | ONI, a biotechnology company democratizing the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, today announced the closing of a $75 million Series B financing. The round was led by ARCH V... |
| 20.01.2022 | Super-resolution microscope maker ONI nabs $75M for US expansion, Series B led by ARCH Venture | - |
| 14.09.2021 | BREAKING: AgBiome closes $116m Series D round led by Blue Horizon, Novalis LifeSciences | US-based crop protection products company AgBiome has raised $116 million in a Series D funding round co-led by Blue Horizon Ventures and Novalis LifeSciences.
Additional participants included new and incumbent investors such as Bayer, Fide... |
| 14.09.2021 | AgBiome closes $116m Series D round led by Blue Horizon, Novalis LifeSciences | US-based crop protection products company AgBiome has raised $116 million in a Series D funding round co-led by Blue Horizon Ventures and Novalis LifeSciences.
Additional participants included new and incumbent investors such as Bayer, Fide... |
| 25.08.2021 | Recuro Health Announces Its $15 Million Series A Round Led by ARCH Venture Partners | - |
| 30.07.2021 | DA32 Life Science Tech Acquisition Corp. : Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering | DA32 Life Science Tech Acquisition Corp. (the “Company”) announced today the closing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Class A common stock began trading on The N... |
| 28.07.2021 | DA32 Life Science Tech Acquisition Corp. : Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering | DA32 Life Science Tech Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Class A common stock are expected to be lis... |
| 26.07.2021 | The Trump crackdown hits the SPAC world | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
A close advisor to former President Donald Trump and one of his top fundraisers in 2016, private ... |
| 26.04.2021 | With a third of its capital deployed, Risk & Return is transforming how we think about emergency response | Disasters are, unfortunately, a growth business, and the frontlines that were once distant have moved much closer to home. Wildfires, hurricanes, floods, tornadoes — let alone a pandemic — has forced much of the United States and increasing... |
| 29.01.2021 | Arch raises $1.9B to build another crop of breakthrough biotechs | Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.
Sponsored by Agilent Technologies
How would you like to wi... |
| 29.01.2021 | Arch raises $1.9B to build another crop of breakthrough biotechs | Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.
As with its earlier funds, Arch will use the money to plac... |
| 28.01.2021 | ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies | |
| 28.01.2021 | ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies | - |
| 28.01.2021 | Arch Venture Partners Closes $1.85 Billion Fund | Chicago, IL-based venture capital firm Arch Venture Partners closed Arch Venture Fund XI, at over $1.85 billion.
The new fund will invest in the creation and funding of early stage biotechnology companies.
Arch will invest Fund XI in early ... |
| 04.04.2020 | ARCH Venture Partners Closes $1.46 Billion For Two Funds | ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture Fund X Overage at $1.46 billion
ARCH Venture Partners has announced it closed two new funds called ARCH Venture Fund X and ARCH Venture ... |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
| 02.04.2020 | Arch Venture Partners Closes Two New Funds, at $1.46 Billion | Chicago, IL-based ARCH Venture Partners closed two new funds, with a combined $1.46 billion.
Limited partners include endowments, family offices, sovereign wealth funds and other institutional investors.
ARCH Venture Fund X and ARCH Venture... |
| 02.04.2020 | ARCH Venture Partners Raises $1.5B Over 2 Funds to Back Biotech Companies | As the coronavirus crisis worsens throughout the U.S., a Chicago venture firm just raised nearly $1.5 billion in two new funds to back companies fighting against COVID-19 and other health care challenges.
ARCH Venture Partners announced Thu... |
| 02.04.2020 | Arch raises $1.5B to back early-stage biotechs through accelerating 'healthcare revolution'
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the money across two funds that will deploy cash to help ... |
| 02.04.2020 | Arch raises $1.5B to back early-stage biotechs through accelerating 'healthcare revolution' | Arch Venture Partners has raised $1.5 billion to place another round of bets on early-stage biotechs. The VC shop, which lists Alnylam and Juno among its previous investments, raised the money across two funds that will deploy cash to help ... |
| 02.04.2020 | ARCH Venture Partners raises $1.46 billion across two funds for biotech investing | Against a backdrop where the life-or-death consequences of biotechnology innovation are becoming increasingly apparent as the world races to develop vaccines and therapies to treat COVID-19, life sciences investor ARCH Venture Partners has ... |
| 08.05.2019 | LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform | LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The lates... |
| 22.03.2019 | 11 Under-The-Radar Chicago VCs You Should Know About | In my most-recent Forbes article, I shared about 12 Chicago-based VCs that are behind hot startups both within our region, like G2 Crowd, and beyond, like SpaceX. These firms tend to get a lot of buzz and make national headlines, but they a... |
| 30.10.2018 | Term Sheet — Tuesday, October 30 | CRYPTO FUNDING
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
The fresh infusion of capital will be used to accelerate global expansion and the offering of more cryptocurrencies.
A sourc... |
| 30.10.2018 | Arch Venture sets its sights on raising $600M for Fund X | Bob Nelsen
Bob Nelsen’s VC group Arch Venture Partners has filed paperwork with the SEC expressing its plans to raise $600 million for its tenth fund — its biggest ever. The announcement comes at a time when the biopharma world i... |
| 29.10.2018 | Arch Venture Partners to Raise $600M for Tenth Venture Capital Fund | Arch Venture Partners, a CHicago, IL-based early stage venture capital firm, is seeking to raise $600m for its 10th fund.
Per an SEC filing, ARCH Venture Fund X, L.P., has not raised any sum, yet.
Led by Managing Directors Robert Nelsen, Ke... |
| 29.10.2018 | Chicago-Based ARCH Venture Partners Targets $600M For Tenth Deep Tech Fund | 20 Shares Email Facebook Twitter LinkedIn
Late Friday afternoon, Chicago-based ARCH Venture Partners filed paperwork with the SEC indicating its intent to raise a targeted $600 million for “ARCH Venture Fund X, L.P.”
Follow Crunchbase News ... |
| 17.06.2018 | Mindstrong Health Raises $15M Series B from ARCH Venture Partners | PALO ALTO, Calif.--(BUSINESS WIRE)--Mindstrong Health, a healthcare company dedicated to transforming brain health through measurement science, announced today that it has secured a B round financing of $15 million from a syndicate of leadi... |
| 17.06.2018 | Mindstrong Health Raises $15M Series B from ARCH Venture Partners | PALO ALTO, Calif.--(BUSINESS WIRE)--Mindstrong Health, a healthcare company dedicated to transforming brain health through measurement science, announced today that it has secured a B round financing of $15 million from a syndicate of leadi... |
| 05.05.2018 | AI researcher from Alphabet’s Calico Labs launches startup applying machine learning to drug discovery | To enable the machine learning, we will use high-quality data that has already been collected, but we will also invest heavily in the creation of our own datasets using high throughput experimental approaches, datasets that are designed exp... |
| 06.04.2018 | Juno’s $9B deal helps venture capitalist Bob Nelsen land on Midas List; Seattle investors don’t make cut | Juno’s new headquarters at 400 Dexter Ave. (GeekWire Photo / Kurt Schlosser)
Forbes released its annual Midas List this week and Seattle-area investors are certainly lacking again.
The list, which ranks the top 100 venture capitalists from ... |
| 02.02.2018 | Vividion Therapeutics launches with $50M pledged from Arch Venture Partners and Versant Ventures | - |
| 23.01.2018 | ARCH Venture Leads $20M Series B for Ultivue | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, has announced today that it has closed a $20 million Series B funding round led by exi... |
| 03.01.2018 | ARCH Venture Joins $47 Million Series C For Scholar Rock | SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow
Novel TGF beta 1 inhibitors demonstrate unprecedented selectivity that highlight ... |
| 03.01.2018 | ARCH Venture Joins $47 Million Series C For Scholar Rock | SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow
Novel TGF beta 1 inhibitors demonstrate unprecedented selectivity that highlight ... |
| 14.11.2017 | ImmusanT Raises $40 Million Series C from ARCH Venture and Vatera Healthcare | CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a clinical-stage company developing Nexvax2®, a therapeutic vaccine designed to induce immune tolerance in celiac disease, today announced the completion of a $40 million Series C equity fi... |
| 18.09.2017 | Arch Ventures Joins $55M Series A for LifeMine Therapeutics | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| 18.09.2017 | LifeMine Therapeutics Closes $55M Series A | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| 20.08.2017 | Unity Biotechnology Raises Additional $35M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc. a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of an additional $35 million in Series B financing. This second cl... |
| 25.07.2017 | Rodeo Therapeutics Raises $5.9M Series B from ARCH Venture Partners | SEATTLE--(BUSINESS WIRE)--Accelerator Corporation, a leading life science investment and management firm, today announced a $5.9 million Series A financing in Rodeo Therapeutics Corporation, a company developing small-molecule therapies des... |
| 15.06.2017 | ARCH Venture Leads $14M Funding for Mindstrong Health | Mindstrong Health, a startup transforming the diagnosis and treatment of neuropsychiatric disorders through the power of AI and ubiquitous mobile technology, today announced that it has secured a $14 million round of Series-A funding. Led b... |
| 16.05.2017 | ARCH Venture Joins $12M Series B for Aira | Aira, a mission-driven company dedicated to developing smart products and services that enable blind and low vision individuals (BVI) to lead healthier and more independent lives, today announced that it has raised $12 million in a Series B... |
| 25.04.2017 | ARCH Venture Leads $40M Series B for Sienna Biopharmaceuticals | WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Sienna Biopharmaceuticals, Inc., a privately held, clinical stage medical dermatology and aesthetics company, today announced that it completed a $40 million Series B financing led by existing inve... |
| 16.03.2017 | ARCH Venture Leads $38M Series A for eGenesis | CAMBRIDGE, Mass.--(BUSINESS WIRE)--eGenesis, a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million Series ... |
| 09.03.2017 | Agtech Funding (& Exit) Sheet: $84m Raised in 2 Weeks (+$400m Instacart Series D), Origin Acquires AgSpace | AgSpace, a UK ag big data startup, has been acquired by Origin Enterprises, the ag retailer and agronomy company for £11.4 million ($13.9m). A further payment of £4.8m ($5.9m) will be made if the company reaches its profit targets. AgSpace ... |
| 05.03.2017 | ARCH Venture Leads $900M Series B for GRAIL | MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced that it has raised over $900 million through the first close of its pr... |
| 02.03.2017 | Boragen Raises $10M Series A from ARCH Venture Partners | RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--AgTech Accelerator™, the unique startup accelerator vehicle dedicated to emerging agricultural technologies, today announced the launch of its first AgTech startup, Boragen Inc., with a $10 mil... |
| 02.03.2017 | AgTech Accelerator Launches First Startup Bringing Gates Foundation to Boragen $10m Series A | AgTech Accelerator, the venture development organization, has launched its first startup, Boragen, leading a $10 million Series A for the ag biotech startup.
AgTech Accelerator invested $3 million of its current $20 million capital pool and... |
| 02.02.2017 | ARCH Venture Partners Leads $50M Series A for Vividion Therapeutics | SAN DIEGO--(BUSINESS WIRE)--ARCH Venture Partners and Versant Ventures today announced the launch of Vividion Therapeutics, Inc., a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs us... |
| 02.02.2017 | Vividion Therapeutics Raises $50M in Series A Financing | Vividion Therapeutics, a San Diego, CA-based biotechnology company, raised $50M in Series A financing.
Founding investors are ARCH Venture Partners and Versant Ventures. In conjunction with the financing, Tom Daniel, M.D., Executive Chairma... |
| 10.01.2017 | ARCH Venture Joins $20M Round For Aledade | Aledade, Inc., a national leader in value-based care, today announced it raised an additional $20 million in funding. This funding will accelerate Aledade’s efforts to grow its provider network and expand partnerships with commercial and Me... |
| 10.01.2017 | Aledade Lands $20M to Expand Value-Based Care Network | Aledade, Inc., a provider of in value-based care has raised $20 million in funding that will accelerate Aledade’s efforts to grow its provider network as well as expand partnerships with commercial and Medicare Advantage health led by Bioma... |
| 30.11.2016 | ARCH Venture Leads $43.5M Series A for Nohla Therapeutics | SEATTLE, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, ... |
| 21.11.2016 | ARCH Raises $408.4M for Ninth Fund | ARCH Venture Partners has raised $408.4 million toward a ninth venture capital fund, according to a filing with the SEC.
The fund has a target of $550 million, which appears to have expanded from an earlier $400 million, the filing says. Th... |
| 21.11.2016 | ARCH Raises $408.4M for Ninth Fund | ARCH Venture Partners has raised $408.4 million toward a ninth venture capital fund, according to a filing with the SEC.
The fund has a target of $550 million, which appears to have expanded from an earlier $400 million, the filing says. Th... |
| 21.11.2016 | Arch Venture Partners to Raise Two Venture Capital Funds | Arch Venture Partners, a Chicago, IL-based technology venture capital firm, is to raise two new funds.
According to different forms raised files with the SEC, the funds include:
– ARCH Venture Fund IX, L.P., which aims to raise $550m and ha... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 31.10.2016 | Unity Biotechnology Raises $116M Series B from ARCH Venture Partners | UNITY Biotechnology, Inc., a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, today announced the closing of a $116 million Series B financing.
Coincident with the financi... |
| 26.10.2016 | GMI Raises $40M Series A from ARCH Venture | Irish life-sciences startup, Genomics Medicine Ireland (GMI) has secured Series A investment of $40 million from sovereign and international investors including ARCH Venture Partners, Polaris Partners, the Ireland Strategic Investment Fund,... |
| 26.10.2016 | Genomics Medicine Raises €36m To Fund Research | Life sciences startup Genomics Medicine Ireland has secured investment funding of €36m from sovereign and international investors including the Ireland Strategic Investment Fund (ISIF), Arch Venture Partners, Polaris Partners, Maveron Equit... |
| 26.10.2016 | GMI Raises $40M Series A from GV | Irish life-sciences startup, Genomics Medicine Ireland (GMI) has secured Series A investment of $40 million from sovereign and international investors including ARCH Venture Partners, Polaris Partners, the Ireland Strategic Investment Fund,... |
| 03.10.2016 | ARCH Venture Partners Leads $95M Funding for Carrick Therapeutics | Cambridge Innovation Capital plc, a Cambridge-based investor in technology and healthcare companies, announces that it has invested in Carrick Therapeutics Ltd, a European oncology company, as part of a $95 million funding round backed by s... |
| 28.08.2016 | ARCH Venture Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 28.08.2016 | ARCH Venture Joins $130M Series B for Denali | Denali Therapeutics Inc. announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 millio... |
| 05.08.2016 | Why biotech investments in Washington state have dropped to the lowest levels since 2011 | Biotech investments in Q1 and Q2 have been increasing for the past five years. This year the number dropped to 2011 levels. Source: PricewaterhouseCoopers’ MoneyTree Report.
Seattle’s biotechnology industry has never really taken root — und... |
| 26.07.2016 | Gates Foundation leads $14M funding round for Just Biotherapeutics to battle infectious diseases | Just Biotherapeutics CEO and Founding Partner Jim Thomas
Seattle-based Just Biotherapeutics said Monday it closed a $14 million funding round led by the Bill & Melinda Gates Foundation.
A group of former Amgen scientists founded Just in... |
| 25.07.2016 | ARCH Venture Partners Joins $14M Series A2 for Just Biotherapeutics | SEATTLE--(BUSINESS WIRE)--Just Biotherapeutics, Inc., an organization dedicated to expanding global access to important protein therapeutics, today announced the closing of a $14M Series A2 financing round. The Bill & Melinda Gates Foun... |
| 30.05.2016 | 5AM Ventures has raised $285M for fifth fund (Updated) | Update On Monday, it confirmed the amount in a press release on its website.
In a phone interview with 5AM Founder and Managing Partner Andrew Schwab he confirmed that 5AM Ventures V would be similar to 5 AM Ventures IV. Its investment targ... |
| 23.03.2016 | Seattle biotech investor Robert Nelsen named to Midas List of top performing VCs, propelled by early investment in Juno | Robert Nelsen
Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman, John Doerr and Fred Wilson are known.
But the Seattle venture capitalist is doing OK, outranking some of the highe... |
| 17.03.2016 | Life sciences investors ARCH Venture Partners raising $400M for ninth fund | ARCH Venture Partners maintains offices in Austin, Chicago, Seattle, San Francisco, and Dublin, Ireland. With its first eight funds, it has two $2 billion in assets under management and has invested in some 180 companies.
Some of its more n... |
| 04.02.2016 | Aira.IO raises $2.5M for smartglass navigation tool geared to visually disabled users | In response to emailed questions, Aira.io Co-founder and CEO Suman Kanuganti said the target date for launch is late 2016. It plans to use some of the funding to add 12-15 people, including navigation agents and some “key hires.” To date, i... |
| 11.01.2016 | Daily funding roundup - January 11, 2016 | Cardiorentis secured $60M; BioAlta raised $45M; V-Wave completed $28M funding
Wamda Capital, A Dubai based venture capital firm with Fadi Ghandour as its Chairman & CEO, has invested $1 million in The Luxury Closet, an online marketplac... |
| 10.01.2016 | The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? | But other companies have been touting advances in liquid biopsy screening for some time now. This is hardly the first gander at a pan-cancer test, right? San Diego-based Pathway Genomics, for instance, announced this past summer that it had... |
| 04.01.2016 | Daily funding roundup - January 4, 2016 | Scholar Rock received $36M; DeePoon landed $30M; SilverCar raised $28M Series C funding
Japan-based startup news media The Bridge today announced raising an undisclosed amount of funding from Fuji Startup Ventures and PR Times. Founded in 2... |
| 29.10.2015 | Google Glass-enabled navigation tool for visually disabled users gets seed funding (video) | The organizers noted the length of time it took users to complete tasks and the level of difficulty, success and confidence users had in completing activities with and without assistance from the company’s dashboard.
The company also closed... |
| 01.10.2015 | Top Seattle investors raise $12.5M for new ‘startup studio’ Pioneer Square Labs | The Pioneer Square Labs team, from left to right: Ryan Kosai, Greg Gottesman, Geoff Entress, Ben Gilbert, Aria Haghighi, Marcelo Calbucci, Leah Severe, and Mike Galgon.
Geoff Entress has an impressive resume. The former securities lawyer an... |
| 21.09.2015 | Daily funding roundup - September 21, 2015 | Deciphera bagged $75M; Portea raised $37.5M; Just Biotherapeutics secured $15M
BidFlyer, an Israeli startup that is a white-label platform for airlines, has raised $1 million in funding for its business model, which involves putting small b... |
| 28.08.2014 | ARCH Venture Partners Closes Eighth Venture Capital Fund at over $400M | ARCH Venture Partners, a U.S. technology venture capital firm, closed its eighth venture fund at more than $400m.
ARCH Venture Fund VIII, which exceeded its $250m subscription target by more than $150m, was supported by existing limited par... |
| 27.08.2014 | Big Win for BioTech: Chicago-Based Arch Ventures Raises $400 Million Fund | Several months ago, we attended a panel that addressed the single biggest challenge facing Chicago's healthcare innovation economy - money. At the event, Mike Yang, partner at Baird Capital, stated that the lack of venture dollars was one o... |